Phase lb Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results

被引：2
|
作者：
Park, Keunchil [1 ]
Cho, Byoung Chul [2 ]
Lee, Ki Hyeong [3 ]
Su, Wu-Chou [4 ]
Kim, Sang-We [5 ]
Lin, Chia-Chi [6 ]
Huang, Dennis Chin-Lun [7 ]
Jung, Helen Hayoun [8 ]
Geng, Yuan [9 ]
Tan, Daniel Shao Weng [10 ]
机构：
[1] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[2] Yonsei Univ, Med Ctr, Seoul, South Korea
[3] Chungbuk Natl Univ Hosp, Cheongju, South Korea
[4] Natl Cheng Kung Univ, Med Coll & Hosp, Tainan, Taiwan
[5] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea
[6] Natl Taiwan Univ Hosp, Taipei, Taiwan
[7] Boehringer Ingelheim Taiwan Ltd, Taipei, Taiwan
[8] Boehringer Ingelheim Korea, Seoul, South Korea
[9] Boehringer Ingelheim China Investment Co Ltd, Shanghai, Peoples R China
[10] Natl Canc Ctr, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
phase Ib; afatinib; BI; 836845; NSCLC;
D O I：
10.1016/j.jtho.2016.11.1672
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02b005
引用
收藏
页码：S1187 / S1188
页数：2
相关论文
共 50 条
  • [1] Phase Ib Trial of Afatinib and BI 836845 in Advanced Non-Small Cell Lung Cancer (NSCLC)
    Park, Keunchil
    Lin, Chia-Chi
    Huang, Dennis Chin-Lun
    Shin, Heather Hye-Jung
    Bogenrieder, Thomas
    Tan, Daniel S. -W.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S554 - S555
  • [2] Phase Ib trial of afatinib and BI 836845 in advanced non-small cell lung cancer (NSCLC)
    Tan, D.
    Lin, C. -C.
    Huang, D. Chin-Lun
    Jung, H.
    Bogenrieder, T.
    Park, K.
    ANNALS OF ONCOLOGY, 2015, 26 : 147 - 147
  • [3] Phase I dose escalation (esc) trial of weekly intravenous (i.v.) BI 836845 in Japanese patients (pts) with advanced solid tumors
    Doi, T.
    Shitara, K.
    Naito, Y.
    Kuboki, Y.
    Kojima, T.
    Hosono, A.
    Yoshino, T.
    Kawamoto, H.
    Tadayasu, Y.
    Ugai, H.
    Takeuchi, Y.
    Bogenrieder, T.
    Yoh, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Phase I trial of fruquintinib in patients with advanced solid tumors; Results of the dose escalation phase
    Wang-Gillam, A.
    Yeckes-Rodin, H.
    Kosmo, M. A.
    Stanton, T.
    Park, H.
    Songhua, F.
    Sauter, N. P.
    Kania, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 175 - +
  • [5] A Phase 1 Trial of Sapanisertib and Telaglenastat (CB-839) in Patients with Advanced NSCLC (NCI 10327): Results from Dose Escalation
    Riess, J.
    Frankel, P.
    Massarelli, E.
    Nieva, J.
    Lai, W. -C. V.
    Koczywas, M.
    Shackelford, D.
    Lanza, I.
    Reid, J. M.
    Gonsalves, W. I.
    Remick, A. J.
    Gandara, D. R.
    Piekarz, R.
    Lara, P. N.
    Newman, E.
    Villalona-Calero, M.
    Paik, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S91 - S92
  • [6] Results of a National Test Run of Treatment Plans for the Standard Arm of a Dose Escalation Trial for Locally Advanced NSCLC
    Nielsen, Tine Bjorn
    Brink, Carsten
    Moller, Ditte Sloth
    Hoffmann, Lone
    Lutz, Christina Maria
    Appelt, Ane L.
    Lund, Mikkel D.
    Nielsen, Martin Skovmos
    Sibolt, Patrik
    Larsen, Christina
    Ottoson, Wiviann
    Schytte, Tine
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S245 - S246
  • [7] A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors
    Chu, Quincy S.
    Sangha, Randeep
    Hotte, Sebastien J.
    Sergenson, Gwen
    Schnell, David
    Chand, Vikram K.
    Hirte, Hal W.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1226 - 1235
  • [8] A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors
    Quincy S. Chu
    Randeep Sangha
    Sebastien J. Hotte
    Gwen Sergenson
    David Schnell
    Vikram K. Chand
    Hal W. Hirte
    Investigational New Drugs, 2014, 32 : 1226 - 1235
  • [9] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial)
    Varga, Andreea
    Baldini, Capucine
    Martin-Romano, Patricia
    Hollebecque, Antoine
    Gazzah, Anas
    Bahleda, Rastislav
    Menis, Jessica
    Champiat, Stephane
    El-Dakdouki, Yolla
    Paoletti, Xavier
    Ribrag, Vincent
    Michot, Jean-Marie
    Rafie, Saloomeh
    Planchard, David
    Besse, Benjamin
    Massard, Christophe
    Soria, Jean-Charles
    Marabelle, Aurelien
    CANCER RESEARCH, 2018, 78 (13)
  • [10] Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
    Varga, Andreea
    Baldini, Capucine
    Martin-Romano, Patricia
    Besse, Benjamin
    Planchard, David
    Champiat, Stephane
    Angevin, Eroc
    Hollebecque, Antoine
    Bahleda, Rastislav
    Gazzah, Anas
    Armand, Jean-Pierre
    Paoletti, Xavier
    Massard, Christophe
    Soria, Jean-Charles
    Marabelle, Aurelien
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345